tiprankstipranks
Trending News
More News >
Advertisement

BINV - AI Analysis

Compare

Top Page

BINV

Brandes International ETF (BINV)

Rating:58Neutral
Price Target:
$41.00
The Brandes International ETF (BINV) has a balanced overall rating, reflecting a mix of strong and weaker holdings. Top contributors like Sanofi and GSK boost the fund's score with their solid financial performance, strategic growth initiatives, and favorable valuations. However, weaker holdings such as Takeda Pharmaceutical, which faces bearish technical momentum and revenue growth challenges, slightly weigh down the overall rating. Investors should note the fund's exposure to diverse sectors and regions, which may help mitigate risks but could also introduce volatility.
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid year-to-date returns, indicating strong overall performance in 2023.
Global Diversification
The fund invests across multiple countries, including the USA, France, Japan, and Switzerland, reducing reliance on any single market.
Exposure to Defensive Sectors
With significant investments in Consumer Defensive and Health Care sectors, the ETF is positioned to perform well during economic uncertainty.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
Underperforming Holdings
Some top holdings, such as Carrefour, have delivered weak or negative year-to-date performance, potentially dragging down overall returns.
Moderate U.S. Concentration
With over 40% of its geographic exposure in the USA, the fund may be sensitive to U.S. market fluctuations despite its international focus.

BINV vs. SPDR S&P 500 ETF (SPY)

BINV Summary

The Brandes International ETF (BINV) is an investment fund that focuses on international companies, particularly those considered undervalued with growth potential. It includes a mix of developed and emerging market stocks, with holdings in well-known companies like Sanofi and Alibaba. This ETF is designed for investors seeking diversification and long-term growth by investing in global markets. However, new investors should be aware that its performance can be affected by fluctuations in international markets and currency changes.
How much will it cost me?The Brandes International ETF (BINV) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because it is actively managed, meaning experts are selecting stocks rather than following a passive index.
What would affect this ETF?The Brandes International ETF (BINV) could benefit from global economic recovery and increased consumer spending, particularly in sectors like Consumer Defensive and Health Care, which are heavily weighted in its portfolio. However, it may face challenges from rising interest rates or geopolitical tensions that could impact international markets and the performance of its top holdings, such as Sanofi and Alibaba. Additionally, regulatory changes in emerging markets could pose risks to some of its investments.

BINV Top 10 Holdings

The Brandes International ETF (BINV) is leaning heavily on global consumer and healthcare giants to drive performance, with names like Sanofi and GlaxoSmithKline showing steady growth thanks to strong earnings and strategic positioning. Alibaba has been a standout, rising sharply on the back of its AI and cloud expansion, while Kering has also gained momentum despite challenges in its luxury segments. However, Heineken and STMicroelectronics have been mixed, with recent dips tempering their earlier gains. The fund’s focus on value stocks across developed and emerging markets adds a layer of diversification, but its tilt toward consumer and healthcare sectors is clear.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Sanofi3.04%$9.42M€107.19B-3.86%
77
Outperform
Alibaba2.94%$9.12M$420.11B82.34%
79
Outperform
Kering2.77%$8.58M$46.40B52.47%
71
Outperform
GlaxoSmithKline2.63%$8.14M$92.97B24.10%
71
Outperform
The Swatch Group AG2.52%$7.80MCHF9.13B0.57%
69
Neutral
2.51%$7.77M
Takeda Pharmaceutical Co2.47%$7.65M¥6.71T1.22%
62
Neutral
Heineken Holding NV2.19%$6.79M€16.83B-7.22%
76
Outperform
2.16%$6.69M
Wilmar International2.15%$6.65MS$19.60B-1.63%
69
Neutral

BINV Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
38.17
Positive
100DMA
37.03
Positive
200DMA
34.79
Positive
Market Momentum
MACD
0.32
Negative
RSI
58.12
Neutral
STOCH
69.69
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BINV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.79, equal to the 50-day MA of 38.17, and equal to the 200-day MA of 34.79, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 58.12 is Neutral, neither overbought nor oversold. The STOCH value of 69.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BINV.

BINV Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$312.24M0.70%
58
Neutral
$650.44M0.50%
64
Neutral
$529.27M0.60%
71
Outperform
$253.11M0.49%
66
Neutral
$186.13M0.60%
69
Neutral
$168.63M0.80%
56
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BINV
Brandes International ETF
39.08
8.62
28.30%
FEGE
First Eagle Global Equity ETF
BKDV
BNY Mellon Dynamic Value ETF
FPAG
FPA Global Equity ETF
GMOI
GMO International Value ETF
COPY
Tweedy Browne Insider + Value ETF Trust Units
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement